Being more physically active, following a balanced diet, not smoking, and keeping body weight and blood pressure under ...

SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight ...

In the 21st century, oncology has achieved extraordinary progress. We can decode a tumor’s genome, tailor therapies to ...

UC San Diego scientists discover enzyme responsible for scrambling cancer genomes; results could enable new treatments for ...

Researchers at the Icahn School of Medicine at Mount Sinai have developed a first-of-its-kind mRNA system that switches on therapeutic genes preferentially inside targeted cells—an advance ...

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 2.5% in the afternoon session after the ...

This immunotherapy treatment holds promise beyond rectal cancer. In early studies of people with esophageal, bladder, or ...

hLife adopts format-free submission. Format-free submission means that, provided you include everything necessary for review ...

University of California San Diego researchers have discovered the enzyme responsible for chromothripsis, a process in which ...

NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026. FORT ...

Menopausal hormone therapy (MHT) does not raise breast cancer risk in women with breast cancer gene mutations, while estrogen only MHT leads to reduced risk.